Letybo

Botulinum toxin type A, the active ingredient in Letybo, is a neurotoxin presented as a sterile injectable for intramuscular use. It temporarily reduces muscle activity in several neuromuscular conditions and is administered by a qualified healthcare professional. GNH USA supplies Letybo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Letybo, a botulinum toxin type A product, acts on overactive muscle activity in several neurological disorders. - Cervical dystonia: reduces abnormal neck muscle contractions and associated pain. - Blepharospasm: relieves involuntary eyelid closure. - Upper‑limb spasticity: improves range of motion and functional use of the arm. - Chronic migraine: decreases the frequency of headache days. - Axillary hyperhidrosis: reduces excessive sweating in the underarm area.

Letybo may cause a range of adverse reactions following intramuscular injection.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Bruising: localized discoloration due to minor bleeding. - Headache: transient headache after treatment. - Localized muscle weakness: temporary reduction in strength of nearby muscles. - Flu‑like symptoms: mild fever, fatigue, or malaise.

Serious or Rare Side Effects: - Dysphagia: difficulty swallowing that may require medical attention. - Respiratory compromise: reduced breathing capacity due to spread of toxin. - Allergic reaction: rash, itching, or anaphylaxis in susceptible individuals. - Systemic botulism‑like symptoms: generalized weakness, vision changes, or drooping eyelids. - Vision changes: blurred vision or double vision.

Before using Letybo, clinicians should consider several safety measures. - Neuromuscular disease assessment: evaluate for conditions such as myasthenia gravis. - Infection risk: avoid injection into areas with active infection. - Anticoagulant use: monitor for increased bruising or bleeding. - Spread of toxin: observe for symptoms beyond the injection site. - Hypersensitivity: contraindicated in patients with known allergy to botulinum toxin type A. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Letybo can interact with other medications that affect neuromuscular transmission.

Major Interactions (Avoid): - Aminoglycoside antibiotics: may potentiate neuromuscular blockade. - Quinine: can increase risk of severe muscle weakness. - Dantrolene: may enhance the paralytic effect.

Moderate Interactions (Monitor Closely): - Anticholinesterase agents: may reduce the efficacy of botulinum toxin. - Calcium channel blockers: possible additive muscle relaxation. - General anesthetics (e.g., succinylcholine): increased risk of prolonged paralysis. - Muscle relaxants: monitor for excessive weakness. - Botulinum antitoxin: may neutralize therapeutic effect.